MN-VÄRDE-PARTNERS
12.10.2020 13:02:13 CEST | Business Wire | Press release
Värde Partners, a leading global alternative investment firm, today announced the promotion of Jon Fox to the role of President and Andy Lenk to the role of Deputy CEO, effective immediately. These appointments are the latest in a series of transition steps which previously included the appointment of Ilfryn Carstairs as Co-CEO and CIO and the promotions of Brad Bauer and Giuseppe Naglieri as Deputy CIOs.
“I’ve often said that transition is a process involving the entire firm and a number of leaders,” said George Hicks, Co-Founder and Co-CEO. “The appointments reflect the many contributions of Jon and Andy to the success and growth of the firm as well as the leadership experience and capabilities that they will bring to the years ahead.” Previously announced in July 2019, George intends to move to an Executive Chair role at the end of 2021.
Ilfryn Carstairs added, “These promotions are an important step in ensuring that we have the right senior leadership team for the next chapter at Värde. I’ve worked very closely with Jon and Andy for many years and I’m excited to see this elevation in their roles.”
In addition to the President and Deputy CEO roles, Värde announced promotions and role changes within the areas of Financial Services, Insurance, and Capital Markets:
- Elena Lieskovska, Partner, will head a new, dedicated Insurance business after leading this effort within the Financial Services team and previously leading specialty finance investing in Europe.
- Aneek Mamik, Senior Managing Director, will be promoted to Global Co-Head of Financial Services from his current role leading those investments in North America and Asia. He will oversee the global team with Partner Rick Noel.
- Craig Rydqvist, Senior Managing Director and Global Head of Capital Markets based in London, will join the Financial Services team to lead investments outside of North America.
- Missy Dolski, Managing Director, will be promoted to Global Head of Capital Markets from her current role as Head of Capital Markets for North America.
Commenting on these appointments, Deputy CIO Brad Bauer said, “We’re excited to announce these promotions which align proven leadership talent with significant areas of opportunity for our investors. These individuals represent the breadth and depth of talent we have in our investing teams and these promotions are well deserved in light of their contributions.”
Jon Fox is a Partner and the head of the New York office who joined the firm in 2013 in London. He has led the firm’s global Business Development and Investor Relations team, fund and product development, and also oversees Communications and Public Affairs. He is a member of the firm’s Investment Committee and Senior Leadership Committee and plays an important role in general management decisions. In 2018, Jon relocated from London to become the head of the firm’s New York office. He will maintain all existing leadership responsibilities as President and further develop Värde’s global industry relationships.
Jon holds a B.A. from the University of Colorado, an M.B.A. from Columbia Business School and serves on the boards of trustees of the Fire Department of New York (FDNY) Foundation and Oliver Scholars and on the Business Council of the Asia Society.
Andy Lenk joined the firm in 2001 and is a Partner in Minneapolis. As Global Head of Strategy and Portfolio Operations, he works closely with the Co-CEOs on all aspects of firm strategy, finance, talent and operations. He is a member of the firm’s Investment Committee, Senior Leadership Committee and the Enterprise Risk Management Committee. Andy has held many leadership roles for the firm including oversight and development of global Portfolio Operations, Capital Markets, Asset Management and the firm’s Finance and Operations functions. Earlier in his career at Värde, Andy worked in investing teams in both the U.S. and Europe.
Andy received a B.B.A. in Accounting from the University of Wisconsin-Madison and an M.B.A. from the University of Michigan. He is a CPA (inactive).
About Värde Partners
Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $75 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
